Search results for Bevacizumab

Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade, ProteoGenix, PX-TA1006

Description of Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade General information about Bevacizumab Bevacizumab, is classified as a monoclonal antibody and/or anti-angiogenesis drug. It is a comparatively new type of cancer therapy. Antibodies are an essential part of the immune system. The body creates antibodies in response to an antigen entering the body. These antibodies attach themselves to the antigen, to mark it for destruction by the body’s immune system. Bevacizumab allows human body to target specific cells, causing less toxicity to healthy cells. It works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis. This product is for research use only.

Bevacizumab, Kyinno, KB-1136

Bevacizumab, Affinityimmuno, ab-131-bevacizumab

Bevacizumab, Abbexa, abx831004

Bevacizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

Bevacizumab Antibody, Abbexa, abx376595

Bevacizumab Antibody is a rabbit polyclonal antibody for the detection of Bevacizumab.

Bevacizumab ELISA Kit, Abbexa, abx395076

Bevacizumab ELISA Kit is a quantitative ELISA kit for detection of Bevacizumab.Bevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.

Anti-Bevacizumab Polyclonal Antibody, AntibodySystem, PAD12602

Bevacizumab Biosimilar - Research Grade, ichor.bio, ICH4003

Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bevacizumab.

Research Grade Bevacizumab (HB941026), abinScience, HB941026

Human Anti-Bevacizumab ELISA Kit, Abbexa, abx392367

Human Anti-Bevacizumab ELISA Kit is a quantitative ELISA kit for detection of antibodies against Bevacizumab.